Genmab
NASDAQ:GMABBiotechCopenhagen, Denmark, Denmark · Est. 1999 · 2,400 employees
Genmab is a Danish biotechnology company developing monoclonal antibody-based therapies for cancer, inflammation, and other diseases.
8
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
105
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
8 drugs in development
Phase 23
Phase 15
Preclinical3
By Therapeutic Area
top 1
Oncology
788%
R&D Momentum
67/100
Pipeline Velocity
41/100
Trial Completion Rate
28/100
Pipeline Concentration
78/100
Pipeline Freshness
71/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
Activity
Recent Activity
Last 14 days
Nov 5, 2026
Active, not recruiting
Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma - A Phase 1/2, Open-Label, Dose-Escalation Trial With Expansion Cohorts
Nov 5, 2026
Recruiting
Phase 1/2 Study of Rina-S in Patients With Locally Advanced and/or Metastatic Solid Tumors
Nov 5, 2026
Recruiting
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
Nov 5, 2026
Active, not recruiting
A Phase 1/2, Open-label Safety Trial of GEN3013 in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
Nov 5, 2026
Terminated
A First-In-Human, Open-Label, Dose Escalation Trial to Evaluate the Safety and Antitumor Activity of GEN1057 in Subjects With Malignant Solid Tumors
Nov 5, 2026
Active, not recruiting
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
Nov 5, 2026
Recruiting
An Open-Label, Multicenter, First-in-Human Trial of GEN3018 in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome
Nov 5, 2026
Active, not recruiting
Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma
Nov 4, 2026
Recruiting
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
Nov 4, 2026
Recruiting
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer
Nov 4, 2026
Active, not recruiting
A Phase 1 Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GEN1042 Monotherapy and in Combination With Pembrolizumab ± Chemotherapy in Japanese Subjects With Malignant Solid Tumors
Nov 4, 2026
Active, not recruiting
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
Details
Company Info
Company Overview
$19.0B
Mkt Cap
$2.5B
Revenue
—
Cash
CEOJan van de Winkel
Founded1999
Employees2,400
HQCopenhagen, Denmark, Denmark
ExchangeNASDAQ:GMAB
Websitegenmab.com
LinkedInCompany Page
Therapeutic Focus
OtherOncologyHematology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Oncology
Oncology
Regulatory
Regulatory Timeline
20232 events
FDAMay 19
Epkinly — EPKINLY
Application BLA761324 (BLA)
FDAMay 19
Epkinly — EPKINLY
Application BLA761324
20241 event
FDAJun 26
Epkinly — EPKINLY
Application BLA761324
20252 events
FDANov 18
Epkinly — EPKINLY
Application BLA761324
FDASep 11
Epkinly — EPKINLY
Application BLA761324
20262 events
FDAJun 17
Epkinly — EPKINLY
Application BLA761324
FDAMar 27
Epkinly — EPKINLY
Application BLA761324
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)